Study of Omalizumab in Moderate to Severe Bronchial Asthma

NCT00232050 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

327

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Omalizumab

Sponsor

Novartis

Collaborators

[object Object]